Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00954915 · ClinicalTrials.gov registry record · Phase 1
Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe Psoriasis
A Phase 1 study, sponsored by MacroGenics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT00954915: Clinical Trial Phase 1 study, sponsored by MacroGenics.
NCT00954915 is a Phase 1 study that was terminated before completion, run by MacroGenics. The registered enrollment target is 1 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00954915, a Phase 1 study, was terminated before completion, sponsored by MacroGenics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether teplizumab is safe when administered subcutaneously (by needle under the skin) in subjects with psoriasis. The study will also evaluate how long teplizumab stays in the blood and how long it takes for it to leave the body, what is the highest dose that can safely be given, and whether it improves psoriasis.
Primary Outcome
Primary endpoints include safety data such as vital signs, physical examinations, electrocardiograms, AE reports, and laboratory test results.
Interventions
- BIOLOGICAL teplizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2009-12 |
| Est. Completion | 2010-07 |
| Phase | Phase 1 |
Why NCT00954915 stopped before completion
NCT00954915 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which teplizumab is the first listed.
NCT00954915 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00954915 about?
NCT00954915 is a clinical study titled "Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe Psoriasis". The purpose of this study is to determine whether teplizumab is safe when administered subcutaneously (by needle under the skin) in subjects with psoriasis. The study will also evaluate how long teplizumab stays in the blood and how long it takes for it to leave the body, what is the highest dose th...
What is the current status of trial NCT00954915?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2009-12. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00954915?
The interventions under investigation include: teplizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00954915?
This trial is sponsored by MacroGenics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00954915's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia